Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status

By afschroeder • October 25, 2025

Bazhenova L, Hodgson JG, Camidge DR, Langer CJ, Huber RM, Kim DW, Reckamp KL, Ahn MJ, Tan DSW, Patel JD, Vincent S, Li C, Humphries MJ, Zhang P, Rivera VM, Gettinger S. Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status. Clin Lung Cancer. 2025 Nov;26(7):e503-e513.e11. doi: 10.1016/j.cllc.2025.05.016. Epub 2025 Jun 6. PMID: 40582920.

Tags: ALK inhibitors, Cedars Sinai DoM, circulating tumor DNA, G1202R, Hematology/Oncology, Publications, Resistance mutations, Tumor biopsy

Sexually Distinct Multi-Omic Responses to Progressive Endurance Exercise Training in the Rat Lung – Findings from MoTrPAC

Many GM, Sagendorf TJ, Mitchell H, Sanford JA, Cohen S, Misra R, Estevao I, Díaz Ludovico I, Gaul DA, Lindholm ME, Ushakumary MG, Pino J,[...]

Surveying patients to assess timeliness of cancer diagnosis

O'Hanlon CE, Berdahl C, Ye F, Ohana E, Tolpadi A, Bradley MA, Marsolais E, Ptacek M, Henreid AJ, Anhang Price R. Surveying patients to assess[...]

The REgistry of Flow and Perfusion Imaging for Artificial Intelligence with positron emission tomography (REFINE PET):Rationale and design

Ramirez G, Lemley M, Shanbhag A, Kwiecinski J, Miller RJH, Kavanagh PB, Liang JX, Dey D, Slipczuk L, Travin MI, Alexanderson E, Carvajal-Juarez I, Packard[...]